Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • IBD

    - PMLiVE

    Abivax shares positive late-stage results for obefazimod in ulcerative colitis

    Inflammatory bowel disease affects nearly one in every 100 people in the US

    - PMLiVE

    Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis

    More than 2.5 million people in Europe are affected by the inflammatory bowel disease

    - PMLiVE

    Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease

    An estimated three million people in the US are affected by inflammatory bowel disease

    - PMLiVE

    J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial

    Inflammatory bowel disease affects almost one in every 100 people in the US

    - PMLiVE

    Eli Lilly shares two-year results for Omvoh in active Crohn’s disease patients

    Inflammatory bowel disease affects almost one in every 100 people in the US

    - PMLiVE

    ICR researchers uncover new method for predicting bowel cancer risk in IBD patients

    Approximately 500,000 people in the UK are affected by Crohn’s disease or ulcerative colitis

    - PMLiVE

    Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study

    Approximately three million people in Europe are affected by inflammatory bowel disease

    - PMLiVE

    Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults

    The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease

    - PMLiVE

    AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition

    The deal includes an IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease

    - PMLiVE

    Eli Lilly’s Omvoh recommended by CHMP to treat Crohn’s disease in adults

    The drug is already approved in the EU to treat ulcerative colitis, another form of inflammatory bowel disease

    - PMLiVE

    Eli Lilly’s mirikizumab shows promise in phase 3 Crohn’s disease study

    Inflammatory bowel disease affects almost one in every 100 people in the US

    - PMLiVE

    Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis

    The inflammatory bowel disease is estimated to affect more than one million people in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links